Tagger Launches Q2 2023 Fashion Index Highlighting Top Brands in Influencer Marketing
7.9.2023 19:00:00 EEST | Business Wire | Press release
Tagger by Sprout Social, the global technology leader in making influencer marketing more intelligent, releases its Q2 Fashion Influencer Marketing Index today. The report highlights which fashion brands have seen the most success from influencer marketing and how others can tap into the insights behind millions of sponsored posts to drive sales and brand awareness.
Leveraging Tagger’s social intelligence engine, Signals, the report looks at overall platform performance for the second quarter. The Fashion Influencer Marketing Index shows an impressive 446,000 influencers posting 15.6 million times about fashion-related content, with Instagram leading the pack with the most posts. However, TikTok continues to drive results for brands, with the highest engagement rate of any platform at 2.18%.
“Our quarterly Fashion Report is one of our favorites to build within our Signals platform, as the industry always leads the way with new and innovative ways to work with influencers,” said Dave Dickman, Global Head of Sales and Services at Tagger by Sprout Social. “One of the more interesting points from this quarter’s report is the international reach of influencers and the ability for one person to catapult an entire city into the spotlight.”
Here are some key takeaways from the latest Fashion Influencer Marketing Report:
- Format is Everything: While TikTok’s engagement rate dropped 15%, it continues outperforming other platforms, including Instagram, by more than 120%.
- The Very Best: ZARA tops the list as the most-mentioned brand among influencers for the second quarter in a row, with Nike and Christian Dior as the second and third, respectively.
- Hashtags Rule the Day: This quarter’s report highlights which hashtags influencers use to better drive engagement, with #fashion and #ootd leading the way.
For Tagger’s full Q2 Fashion Influencer Marketing Report, visit: https://www.taggermedia.com/research/fashion-index-q2-2023
About the Data
The data referenced in the Q2 Fashion Influencer Marketing Report was collected via Tagger’s social intelligence engine, Signals. It looks at fashion-related posts from influencers globally across social platforms from April 1, 2023, through June 31, 2023.
About Tagger by Sprout Social
Tagger by Sprout Social is a global leader in revolutionizing how top brands and agencies harness data and analytics to drive creator and influencer marketing strategies. Trusted by global enterprises, Tagger is a disruptive SaaS solution that offers unparalleled expertise. Leveraging API partnerships with major social channels, Tagger connects millions of brand and influencer profiles to billions of social data points, offering the industry’s most robust social intelligence and actionable insights. Tagger’s platform provides powerful analytics, all-in-one capabilities, and strategic integrations for efficient campaign workflows. To learn more, visit www.taggermedia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907466701/en/
Contact information
Katie Huff
Trevelino/Keller
404.214.0722
khuff@trevelinokeller.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom